Cyclana Bio

Based in the UK, Cyclana Bio develops innovative tissue-based therapeutic solutions focused on women's health, particularly in addressing conditions like endometriosis. Founded in 2025 in Cambridge, UK, Cyclana Bio specializes in creating therapies aiming to improve women's health. The company has secured GBP 5 million in funding, with its most recent deal finalized on October 20, 2025, involving investors such as NFX and Eka Ventures. No significant pivots or changes in operations have been noted.

Cyclana Bio specializes in the development of innovative therapeutic solutions targeted at women's health, specifically addressing endometriosis. The company utilizes menstrual fluid to create advanced physiological assays that replicate human diseases, which enhances the understanding of women's health conditions and facilitates the discovery of new health insights. Their core products and services are designed for healthcare providers, researchers, and institutions focused on women's health across North America and Europe. Cyclana Bio generates revenue through partnerships and collaborations with healthcare institutions and research organizations specialized in women's health.

Their model likely includes contract-based agreements for bespoke assays and analysis services tailored to client research requirements. While specific pricing details are not disclosed, the company's focus on scientifically rigorous offerings indicates a premium positioning in the market. In October 2025, Cyclana Bio raised GBP 5 million in pre-seed funding, which will be utilized to collect more patient samples, enhance its 3D tissue models of endometriosis, and advance its leading drug candidates toward preclinical testing. The company aims to expand its market presence by targeting new regions within North America and Europe, aligning with its strategic goal of addressing women's health challenges through innovative solutions.